<i>In vitro</i> study of a triple‐secured von Willebrand factor concentrate

Abstract

We have perfected a large-scale manufacturing process to produce a human plasma-derived VWF concentrate that boasts high specific activity and is very safe for the treatment of patients with von Willebrand disease.